We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TEM:NASDAQTempus AI, Inc. Analysis

Data as of 2026-09-13 - not real-time

$59.01

Latest Price

9/10Risk

Risk Level: High

Executive Summary

At $59.01, Tempus AI, Inc. shows no decisive moving-average alignment, leaving the trend neutral. Across the trailing 30 sessions it gained 33.2%. With RSI at 48.3 the momentum picture is neutral, alongside a bearish MACD signal. Watch $49.35 as support and $72.96 as the nearer resistance level.
The shares look overvalued, trading on 14752.5 times earnings above a sector average of 29.5. Consensus targets land 15.5% above where the shares trade now. Revenue is growing at 21.6% on a -17.8% profit margin.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 98.3%, a beta of 2.53 and a maximum drawdown of 59.8%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
This one splits by horizon — hold in the near term, sell further out, at 6/10 long-term conviction.

Top Market Events

Tempus AI Inc. TEM stock is surging over 11% on Friday at the time of publication. The price movement is primarily...Personalis holders receive Tempus shares worth $16.Seeking Alpha26dTempus AI: The Data Flywheel Has Started SpinningTempus AI reported its first GAAP profit, accelerated...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 3/10

Key Factors

  • Trading above the 200-day average of 56.27
  • MACD momentum is negative
  • 30-day price change of +33.2%

Medium Term

1–3 years
Cautious
Model confidence: 4/10

Key Factors

  • P/E of 14752.5 versus sector average of 29.5
  • Trading above the 200-day average of 56.27
  • Analyst targets imply +15.5% versus the current price

Long Term

> 3 years
Cautious
Model confidence: 6/10

Key Factors

  • P/E of 14752.5 versus sector average of 29.5
  • Negative profit margin of -17.8%
  • Analyst targets imply +15.5% versus the current price

Key Metrics & Analysis

Financial Health

Revenue Growth21.60%
Profit Margin-17.77%
P/E Ratio14752.5
ROE-67.44%
ROA-8.55%
Debt/Equity324.58
P/B Ratio23.9
Op. Cash Flow$-237432000
Free Cash Flow$-93493376
Industry P/E29.5

Technical Analysis

TrendNeutral
RSI48.3
Support$49.35
Resistance$72.96
MA 20$62.58
MA 50$55.88
MA 200$56.27
MACDBearish
VolumeDecreasing
Fear & Greed Index93.14

Valuation

Target Price$68.18
Upside/Downside15.53%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta2.53
Volatility98.32%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.